Rhumbline Advisers Syndax Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 114,459 shares of SNDX stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114,459

Previous 119,285 4.05%

Holding current value

$1.5 Million

Previous $2.45 Million 10.01%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$17.93 - $24.81 $86,530 - $119,733	-4,826 Reduced 4.05%	114,459 $2.2 Million
Q2 2024 Aug 01, 2024	BUY	$18.82 - $23.79 $193,676 - $244,822	10,291 Added 9.44%	119,285 $2.45 Million
Q1 2024 May 09, 2024	BUY	$19.71 - $24.57 $269,573 - $336,043	13,677 Added 14.35%	108,994 $2.59 Million
Q4 2023 Feb 08, 2024	SELL	$11.39 - $21.67 $41,596 - $79,138	-3,652 Reduced 3.69%	95,317 $2.06 Million
Q3 2023 Nov 09, 2023	BUY	$14.52 - $21.77 $9,742 - $14,607	671 Added 0.68%	98,969 $1.44 Million
Q2 2023 Aug 08, 2023	BUY	$19.35 - $22.31 $144,041 - $166,075	7,444 Added 8.19%	98,298 $2.06 Million
Q1 2023 May 11, 2023	BUY	$20.66 - $28.98 $212,508 - $298,088	10,286 Added 12.77%	90,854 $1.92 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $36,739 - $46,707	1,780 Added 2.26%	80,568 $2.05 Million
Q3 2022 Nov 10, 2022	BUY	$18.51 - $24.79 $139,232 - $186,470	7,522 Added 10.55%	78,788 $1.89 Million
Q2 2022 Aug 11, 2022	BUY	$13.64 - $19.48 $177,688 - $253,765	13,027 Added 22.37%	71,266 $1.37 Million
Q1 2022 May 12, 2022	BUY	$14.84 - $22.15 $22,497 - $33,579	1,516 Added 2.67%	58,239 $1.01 Million
Q4 2021 Feb 10, 2022	SELL	$15.23 - $22.47 $11,818 - $17,436	-776 Reduced 1.35%	56,723 $1.24 Million
Q3 2021 Nov 12, 2021	BUY	$13.87 - $19.8 $29,127 - $41,580	2,100 Added 3.79%	57,499 $1.1 Million
Q2 2021 Aug 05, 2021	BUY	$13.42 - $25.18 $317,128 - $595,028	23,631 Added 74.39%	55,399 $951,000
Q1 2021 May 06, 2021	SELL	$19.28 - $24.59 $17,834 - $22,745	-925 Reduced 2.83%	31,768 $710,000
Q4 2020 Feb 10, 2021	BUY	$15.1 - $26.44 $29,701 - $52,007	1,967 Added 6.4%	32,693 $727,000
Q3 2020 Nov 12, 2020	SELL	$13.39 - $17.48 $40,411 - $52,754	-3,018 Reduced 8.94%	30,726 $454,000
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $91,813 - $215,464	10,270 Added 43.75%	33,744 $500,000
Q1 2020 May 06, 2020	BUY	$6.65 - $12.03 $2,793 - $5,052	420 Added 1.82%	23,474 $258,000
Q4 2019 Feb 05, 2020	BUY	$5.43 - $9.22 $1,102 - $1,871	203 Added 0.89%	23,054 $202,000
Q3 2019 Oct 23, 2019	SELL	$7.47 - $10.76 $1,045 - $1,506	-140 Reduced 0.61%	22,851 $171,000
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $18,257 - $34,689	3,726 Added 19.34%	22,991 $214,000
Q1 2019 May 01, 2019	SELL	$4.26 - $6.86 $617 - $994	-145 Reduced 0.75%	19,265 $101,000
Q4 2018 Jan 31, 2019	BUY	$3.6 - $8.42 $19,260 - $45,047	5,350 Added 38.05%	19,410 $86,000
Q3 2018 Nov 07, 2018	SELL	$6.33 - $8.08 $3,956 - $5,050	-625 Reduced 4.26%	14,060 $114,000
Q2 2018 Aug 06, 2018	BUY	$6.93 - $14.63 $101,767 - $214,841	14,685 New	14,685 $103,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Syndax Pharmaceuticals Inc Transaction History